USSTOCK.TODAY
Regular Market
Log in Sign up

Tarsus Pharmaceuticals records $194.57 million in revenue amid XDEMVY growth

Earnings Whispers +1 · ·by G4L

TARS
TARS Tarsus Pharmaceuticals Inc
$73.83 +4.22%
View chart & analysis →
  1. 1Tarsus Pharmaceuticals recorded $194.57 million in revenue, exceeding expectations.
  2. 2Tarsus Pharmaceuticals achieved a 45.5% surprise in adjusted loss per share compared to consensus.
  3. 3Tarsus Pharmaceuticals raised its annual XDEMVY guidance.

So what's the key point?

Tarsus Pharmaceuticals' revenue came in higher than experts expected. As drug sales performed well, losses decreased and the company raised its target for this year.

Source Earnings Whispers +1 · View original ↗

Related 3-line summaries

Iron Mountain Reports Q2 Profit of $100.4 Million Associated Press +3 · Aug 5Carlsmed Q3 Earnings Release: A Test Between Growth Expectations and Seasonal Off-Season Earnings Whispers +1 · Nov 4Corcept Therapeutics beats Q3 estimates but shares fall on guidance Investing.com +2 · Nov 4
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news